• Contribution of Contrast Enhanced Ultrasound in the Diagnosis of Adnexal Torsion

  NCT04522219

  TerminatedInterventionalPhase 3Updated Apr 8, 2026
• Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

  NCT00248820

  Unknown statusInterventionalNot ApplicableUpdated Nov 22, 2007
• Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery

  NCT02847832

  Unknown statusObservationalUpdated Apr 14, 2020
• Role of Preoperative D-dimer Levels in the Diagnosis of Adnexal Torsion

  NCT06324565

  Unknown statusObservationalUpdated Jun 13, 2024
• Testicular Torsion Evaluation by ultraSonography Technic Imaging

  NCT07133243

  Not yet recruitingObservationalUpdated Aug 20, 2025
• Effect of Fetal Ovarian Cyst Aspiration to Prevent Torsion

  NCT00222066

  CompletedInterventionalNot ApplicableUpdated Feb 3, 2010

ClinicalTrials.gov ID

NCT06677554

Lead Sponsor

Central Hospital, Nancy, FranceOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

256Estimated

Last Update Posted

Apr 8, 2026Actual

Start Date

May 14, 2025Actual

Primary Completion Date

Feb 7, 2028Estimated

Completion Date

Feb 7, 2028Estimated

Official Title

COVARIAN - Contribution of Contrast Enhanced Ultrasound for Diagnosis of Adnexal Torsion: a Randomized Controlled Trial

Brief Summary

Adnexal torsion is the rotation of the ovary around its vascular axis resulting, in the absence of treatment, ischemia that can lead to peritonitis by necrosis or impaired fertility. It is a gynecological emergency affecting 3% of women of childbearing age, including from adolescence, and requires surgical treatment as soon as possible, classically within 6 hours.

The symptomatology of adnexal torsion is dominated by pelvic pain of sudden onset and variable intensity, an aspecific sign that does not allow a diagnosis of certainty. There are no biological markers and, in the context of the emergency, the only imaging examination available is pelvic ultrasound associated with a Doppler flow analysis but with a low and variable diagnostic performance depending on the studies (sensitivity variable from 46 to 73%).

There are currently no tests that can provide a diagnosis of certainty. Only surgical exploration, carried out at the discretion of the practitioner on the basis of a bundle of arguments, can confirm or refute the diagnosis. However, this management strategy leads to the realization of emergency surgical interventions wrongly since 3 out of 10 women will finally not have an adnexal torsion (PMSI data from participating centers: 30 to 45% false positives).

Contrast ultrasound is a technique that uses a strict intravascular product to assess the vascularization of the ovary and offers a high diagnostic performance in the context of adnexal torsion. Indeed, a retrospective study, published in 2021, reports a sensitivity of 94% and a specificity of 100%. The preliminary results of our pilot study (AGATA APJC 2019, Dr Bertholdt, NCT04522219) also go in this direction with a sensitivity of 100%, a specificity of 86% and a negative predictive value of 100% (data being published).

The COVARIAN project, second stage of the AGATA project, aims to demonstrate that the addition of a contrast evaluation to standard ultrasound in the diagnostic strategy in case of suspicion of adnexal torsion improves the health of women by reducing the rate of wrongly surgery, that is, without proven torsion.

COVARIAN will be the first prospective multicenter randomized study evaluating the direct benefit for women of using ultrasound contrast evaluation in the management strategy in case of suspicion of adnexal torsion.

• Adnexal Torsion

• Addition of ultrasound with contrast injection (SonoVue®)
• Standard Care (in control arm)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 18 or over
• Person who has carried out a preliminary clinical examination adapted to the clinical trial
• Strong suspicion of adnexal torsion with surgery planned
• No ongoing pregnancy or breastfeeding
• Affiliation to or beneficiary of a social security scheme
• Person who has received complete information on the organization of the research and has signed their informed consent

Exclusion Criteria:

• Person who does not understand and/or speak French

• Any medical situation that does not indicate the administration of SonoVue®, including:

  • Known hypersensitivity to sulphur hexafluoride or any of the other components of SonoVue
  • Woman with acute coronary syndrome or unstable ischemic heart disease
  • Woman with acute endocarditis
  • Woman with valve prostheses
  • Women with acute systemic inflammatory disease and/or sepsis
  • Woman with hypercoagulation and/or recent thromboembolic accident
  • End-stage woman with kidney or liver disease
  • Woman with right-left shunt, severe pulmonary hypertension (pulmonary arterial pressure > 90 mmHg)
  • Women with uncontrolled systemic hypertension
  • Woman with respiratory distress syndrome
  • Medical condition contraindicating the administration of SonoVue®,

• History of PEG allergy (or macrogol)

• Person referred to in Articles 10, 31, 32, 33 and 34 of Regulation EU 536/2014:

  • Pregnant, parturient or breastfeeding/nursing mother
  • Minor (not emancipated)
  • Adult subject to a legal protection measure (guardianship, curatorship, safeguarding of justice)
  • Person of legal age who is unable to express consent

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Central Hospital, Nancy, FranceOTHER

emmanuel.simon@chu-dijon.fr+33380293852

eraimond@chu-reims.fr+33326789598